CA2411542A1 - Encapsulation d'adn plasmidique (lipogenesmc) et d'agents therapeutiques contenant des conjugues peptidiques a signal de localisation nucleaire/fusogenes dans des complexes ciblesde liposomes - Google Patents

Encapsulation d'adn plasmidique (lipogenesmc) et d'agents therapeutiques contenant des conjugues peptidiques a signal de localisation nucleaire/fusogenes dans des complexes ciblesde liposomes Download PDF

Info

Publication number
CA2411542A1
CA2411542A1 CA002411542A CA2411542A CA2411542A1 CA 2411542 A1 CA2411542 A1 CA 2411542A1 CA 002411542 A CA002411542 A CA 002411542A CA 2411542 A CA2411542 A CA 2411542A CA 2411542 A1 CA2411542 A1 CA 2411542A1
Authority
CA
Canada
Prior art keywords
seq
peptide
nls
dna
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002411542A
Other languages
English (en)
Inventor
Teni Boulikas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regulon Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2411542A1 publication Critical patent/CA2411542A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient

Abstract

L'invention concerne un procédé d'encapsulation de plasmides, d'oligonucléotides ou de médicaments négativement chargés dans des liposomes présentant une composition lipidique différente entre leur bicouches membranaires intérieure et extérieure et capables d'atteindre des tumeurs primaires et leurs métastases après une injection intraveineuse administrée à des animaux et à des humains. Le procédé de formulation comprend une formation de complexe entre l'ADN avec des molécules lipidiques cationiques, et des conjugués de peptides fusogènes/NLS composés d'une chaîne hydrophobe d'environ 10-20 acides aminés et contenant également au moins quatre résidus d'histidine ou NLS au niveau de leur unique extrémité. Les molécules encapsulées présentent une efficacité thérapeutique dans l'éradication d'une variété de tumeurs humaines solides comprenant, notamment, le carcinome mammaire et le carcinome prostatique. Une combinaison de plasmides, d'oligonucléotides ou de médicaments chargés négativement, associée à d'autres médicaments antinéoplasiques (le cis-platine chargé positivement, la doxorubicine) encapsulés dans des liposomes, peut présenter une valeur thérapeutique. Les combinaisons de plasmides, oligonucléotides ou médicaments chargés négativement encapsulés avec HSV-tk plus du ganciclovir encapsulé peuvent également présenter une valeur thérapeutique.
CA002411542A 2000-06-09 2001-06-08 Encapsulation d'adn plasmidique (lipogenesmc) et d'agents therapeutiques contenant des conjugues peptidiques a signal de localisation nucleaire/fusogenes dans des complexes ciblesde liposomes Abandoned CA2411542A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21092500P 2000-06-09 2000-06-09
US60/210,925 2000-06-09
PCT/US2001/018657 WO2001093836A2 (fr) 2000-06-09 2001-06-08 Encapsulation d'adn plasmidique (lipogenesmc) et d'agents therapeutiques contenant des conjugues peptidiques a signal de localisation nucleaire/fusogenes dans des complexes cibles de liposomes

Publications (1)

Publication Number Publication Date
CA2411542A1 true CA2411542A1 (fr) 2001-12-13

Family

ID=22784880

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002411542A Abandoned CA2411542A1 (fr) 2000-06-09 2001-06-08 Encapsulation d'adn plasmidique (lipogenesmc) et d'agents therapeutiques contenant des conjugues peptidiques a signal de localisation nucleaire/fusogenes dans des complexes ciblesde liposomes

Country Status (8)

Country Link
EP (1) EP1292284A2 (fr)
JP (1) JP2003535832A (fr)
CN (2) CN1981873A (fr)
AU (2) AU7542301A (fr)
CA (1) CA2411542A1 (fr)
MX (1) MXPA02012198A (fr)
TW (1) TWI292324B (fr)
WO (1) WO2001093836A2 (fr)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2410224C (fr) * 2000-06-16 2013-08-13 Zealand Pharma A/S Conjugats peptidiques modifies sur les terminaisons n et c ou n ou c par une chaine peptidique courte chargee
WO2001098540A2 (fr) * 2000-06-22 2001-12-27 San Diego State University Foundation Modulateurs de recombinaison et leurs methodes de production et d'utilisation
GB0103110D0 (en) 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
ATE391791T1 (de) * 2000-08-25 2008-04-15 Aventis Pharma Inc Membran penetrierende peptide und deren anwendungen
AU3652602A (en) * 2000-11-15 2002-05-27 Us Gov Health & Human Serv Sol-fusin: use of gp64-6his to catalyze membrane fusion
SE0101702D0 (sv) 2001-05-15 2001-05-15 Ardenia Investments Ltd Novel potentiating compounds
WO2003047493A2 (fr) 2001-12-03 2003-06-12 Dor Biopharma Inc. Compositions a base de micelles inverses et applications
US20040052928A1 (en) 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
CA2513044A1 (fr) 2002-03-01 2004-08-05 Dyax Corp. Peptides de liaison kdr et vegf/kdr et leur utilisation a des fins diagnostiques et therapeutiques
JP2003286198A (ja) * 2002-03-29 2003-10-07 Japan Science & Technology Corp 増殖因子等を提示するタンパク質中空ナノ粒子を用いる治療薬剤
JP2003286199A (ja) * 2002-03-29 2003-10-07 Japan Science & Technology Corp タンパク質中空ナノ粒子を用いる肝臓疾患治療用薬剤
EP3100719A3 (fr) * 2002-05-15 2017-02-22 California Pacific Medical Center Administration de composés de type acide nucléique
DK2286795T3 (en) 2002-06-26 2017-02-06 Syncore Biotechnology Co Ltd PROCEDURE FOR PREPARING A Cationic LIPOSOMAL PREPARATION INCLUDING A LIPOPHIL COMPOUND
EP2338478B1 (fr) 2002-06-28 2014-07-23 Protiva Biotherapeutics Inc. Méthode de préparation de liposomes
EP1530456A2 (fr) * 2002-08-23 2005-05-18 Munich Biotech AG Formulations lipidiques cationiques non vesiculaires
US7491699B2 (en) 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
ATE426575T1 (de) 2003-01-07 2009-04-15 Univ Ramot Peptidenanostrukturen die fremdmaterial enthalten,und verfahren zur herstellung derselben
EP1603535A4 (fr) * 2003-03-18 2008-10-15 Ethicon Inc Diagnostic et traitement faisant appel a un inhibiteur de l'aromatase
EP1638517A4 (fr) 2003-06-30 2010-01-06 Univ Tel Aviv Future Tech Dev Peptides, anticorps diriges contre les maladies associees a l'amyloide et procedes d'utilisation pour le diagnostic et le traitement de ces maladies
US7732479B2 (en) 2004-08-19 2010-06-08 Tel Aviv University Future Technology Development L.P. Compositions for treating amyloid associated diseases
JP4810825B2 (ja) * 2004-12-27 2011-11-09 東洋紡績株式会社 リパーゼ活性測定方法および測定試薬
CA2597170A1 (fr) * 2005-02-08 2006-08-17 Id Biomedical Corporation Of Quebec C.O.B. As Glaxosmithkline Biological S North America Compositions pharmaceutiques
JP5067733B2 (ja) * 2005-03-09 2012-11-07 国立大学法人北海道大学 目的物質をミトコンドリア内に送達可能な脂質膜構造体
JPWO2006101201A1 (ja) * 2005-03-24 2008-09-04 国立大学法人 北海道大学 目的物質を効率的に核内に送達可能なリポソーム
US10004828B2 (en) 2005-10-11 2018-06-26 Romat at Tel-Aviv University Ltd. Self-assembled Fmoc-ff hydrogels
CN100376680C (zh) * 2005-11-01 2008-03-26 暨南大学 双重靶效应基因嵌合重组体及其构建方法和应用
EP1790657A1 (fr) * 2005-11-24 2007-05-30 Technische Universität München Peptides transmembranaires commutable de pH pour stimuler la fusion transmembranaire
GR20060100144A (el) * 2006-03-03 2007-10-17 Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
AU2007303205A1 (en) 2006-10-03 2008-04-10 Tekmira Pharmaceuticals Corporation Lipid containing formulations
CN101610759A (zh) * 2006-11-07 2009-12-23 美国政府卫生与公共服务部 由跨膜肽组成的自组装纳米颗粒及其用于特异性肿瘤内递送抗癌药物的应用
EP2134365B1 (fr) * 2007-03-21 2019-03-13 Effat Emamian Compositions et procédés d'inhibition de la croissance des cellules tumorales
EP2170267A4 (fr) * 2007-06-28 2011-04-27 Agency Science Tech & Res Peptide cationique servant a liberer un agent dans une cellule
JP2009203174A (ja) * 2008-02-26 2009-09-10 Hokkaido Univ タンパク質−リポソーム複合体を含有するイオントフォレーシス用組成物
PL2279254T3 (pl) 2008-04-15 2017-11-30 Protiva Biotherapeutics Inc. Nowe preparaty lipidowe do dostarczania kwasów nukleinowych
WO2010149785A1 (fr) * 2009-06-26 2010-12-29 Universiteit Gent Liposomes cationiques utilisés pour administrer des composés à poids moléculaire élevé
EP2449114B9 (fr) 2009-07-01 2017-04-19 Protiva Biotherapeutics Inc. Formulations lipidiques inédites permettant l'administration d'agents thérapeutiques en direction de tumeurs solides
CN102038640B (zh) * 2009-10-26 2013-11-13 石药集团中奇制药技术（石家庄）有限公司 一种含有胆固醇的peg修饰物的脂质体药物及其制备方法
WO2012000104A1 (fr) 2010-06-30 2012-01-05 Protiva Biotherapeutics, Inc. Systèmes non liposomaux pour une administration d'acide nucléique
JP5940064B2 (ja) 2010-07-06 2016-06-29 ノバルティス アーゲー 低用量のｒｎａを用いた大型哺乳動物の免疫化
BR112013000244A2 (pt) 2010-07-06 2016-05-17 Novartis Ag lipossomas com lipídeos apresentando pka vantajoso para administração de rna
LT3243526T (lt) 2010-07-06 2020-02-10 Glaxosmithkline Biologicals S.A. Rnr pristatymas, skirtas keleto imuninio atsako paleidimui
SI2611461T1 (sl) 2010-08-31 2022-08-31 Glaxosmithkline Biologicals Sa Pegilirani liposomi za dostavo imunogen-kodirajoče RNA
AU2011316707A1 (en) 2010-10-11 2013-05-09 Novartis Ag Antigen delivery platforms
MX2013005413A (es) 2010-11-15 2014-02-27 Univ Ramot Analogos de dipeptidos para el tratamiento de afecciones asociadas con la formacion de fibrillas amiloides.
US9018169B2 (en) 2011-03-18 2015-04-28 Duke University Peptides for suppressing inflammation
US9303063B2 (en) 2011-03-18 2016-04-05 Duke University Peptide compounds for suppressing inflammation
ES2656050T3 (es) 2011-07-06 2018-02-22 Glaxosmithkline Biologicals Sa Composiciones de combinación inmunogénica y usos de las mismas
MX366055B (es) 2011-08-31 2019-06-26 Novartis Ag Liposomas pegilados para admistracion de acido ribonucleico (arn) que codifica para inmunogeno.
JP6249447B2 (ja) * 2012-01-24 2017-12-20 インターケー・ペプチド・セラピューティクス・リミテッド 癌治療用ペプチド剤
DK2911650T3 (da) 2012-10-29 2019-11-18 Agency Science Tech & Res Hidtil ukendt reagens til gen-lægemiddel-terapeutika
CN103211762B (zh) * 2013-04-11 2015-01-14 同济大学 诊疗一体化新型杂化胶束及其制备方法
EP3981437A1 (fr) 2014-04-23 2022-04-13 ModernaTX, Inc. Vaccins à base d'acide nucléique
BR112017006057B1 (pt) * 2014-09-26 2023-11-21 Universidade Estadual Paulista Júlio De Mesquita Filho - Unesp Composição farmacêutica à base de prostaglandina J2 incorporada em sistemas micelares baseados em poloxâmeros para potencialização das atividades analgésica e anti-inflamatória
AU2016275046B2 (en) 2015-06-10 2022-07-28 Board Of Regents, The University Of Texas System Use of exosomes for the treatment of disease
TN2018000155A1 (en) * 2015-10-22 2019-10-04 Modernatx Inc Herpes simplex virus vaccine
AU2017267634C1 (en) * 2016-05-16 2022-05-26 The Board Of Regents Of The University Of Texas System Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
CA3041307A1 (fr) 2016-10-21 2018-04-26 Giuseppe Ciaramella Vaccin contre le cytomegalovirus humain
WO2018170256A1 (fr) 2017-03-15 2018-09-20 Modernatx, Inc. Vaccin contre le virus de l'herpès simplex
SG11202001008RA (en) * 2017-08-25 2020-03-30 Codiak Biosciences Inc Preparation of therapeutic exosomes using membrane proteins
EA202091134A1 (ru) 2017-12-28 2020-11-20 Кодиак Байосайенсес, Инк. Экзосомы для иммуноонкологической и противовоспалительной терапии
JP7436030B2 (ja) * 2017-12-29 2024-02-21 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 複合体及びその調製方法と使用
KR102101179B1 (ko) * 2019-09-20 2020-05-15 건양대학교 산학협력단 유방암유래 암줄기세포의 선택적 표적치료를 위한 나노복합체 제조방법
KR102164218B1 (ko) * 2019-09-24 2020-10-12 코스맥스 주식회사 피부 흡수 증진을 위한 다중층 양이온성 리포좀 및 이의 제조방법
WO2022045009A1 (fr) * 2020-08-24 2022-03-03 国立大学法人山口大学 Composition de traçage de fluide et procédé de traçage de fluide
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
CA3200234A1 (fr) 2020-11-25 2022-06-02 Daryl C. Drummond Nanoparticules lipidiques utilisees pour l'administration d'acides nucleiques, et methodes d'utilisation associees
CN114762679B (zh) * 2021-01-13 2023-04-07 上海交通大学医学院 一种纳米复合物及其制备方法和用途
CN113406957B (zh) * 2021-05-19 2022-07-08 成都理工大学 基于免疫深度强化学习的移动机器人自主导航方法
CN113546180A (zh) * 2021-05-25 2021-10-26 重庆医科大学 一种具有心肌靶向性的基因递送载体及其制备方法
WO2023001156A1 (fr) * 2021-07-19 2023-01-26 Wuhan University Compositions et procédés pour l'administration efficace de polynucléotides à des cellules
EP4230638A1 (fr) * 2022-02-16 2023-08-23 Lipotrue, S.L. Peptides et compositions à utiliser dans des produits cosmétiques
CN114632062A (zh) * 2022-03-21 2022-06-17 南京大学 一种用于递送核酸药物的中性脂质体及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635487A (en) * 1994-12-29 1997-06-03 Wolff; Jon A. Amphipathic, micellar delivery systems for biologically active polyions
US6120794A (en) * 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
FR2754272B1 (fr) * 1996-10-08 1998-11-13 Rhone Poulenc Rorer Sa Procede de preparation de compositions pour le transfert d'acides nucleiques
AU740342B2 (en) * 1997-12-12 2001-11-01 Samyang Corporation Biodegradable mixed polymeric micelles for gene delivery

Also Published As

Publication number Publication date
AU2001275423B2 (en) 2007-01-11
MXPA02012198A (es) 2004-08-19
WO2001093836A2 (fr) 2001-12-13
AU7542301A (en) 2001-12-17
WO2001093836A3 (fr) 2002-10-03
JP2003535832A (ja) 2003-12-02
EP1292284A2 (fr) 2003-03-19
CN1444472A (zh) 2003-09-24
TWI292324B (en) 2008-01-11
CN1981873A (zh) 2007-06-20
CN1254234C (zh) 2006-05-03

Similar Documents

Publication Publication Date Title
US9278067B2 (en) Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
AU2001275423B2 (en) Encapsulation of polynucleotides and drugs into targeted liposomes
AU2001275423A1 (en) Encapsulation of polynucleotides and drugs into targeted liposomes
Magar et al. Liposome-based delivery of biological drugs
Ferreira et al. pH-sensitive liposomes for drug delivery in cancer treatment
US7393478B2 (en) Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
JP6137894B2 (ja) リポソーム−エキソソームハイブリッドベシクル及びその調製法
AU2003205049B2 (en) Efficient nucleic acid encapsulation into medium sized liposomes
PL199201B1 (pl) Pęcherzyk lipidowy, sposób wytwarzania pęcherzyka lipidowego oraz zastosowanie pęcherzyka lipidowego
Nsairat et al. Recent advances in using liposomes for delivery of nucleic acid-based therapeutics
Le Saux et al. Interest of extracellular vesicles in regards to lipid nanoparticle based systems for intracellular protein delivery
WO2003057190A1 (fr) Encapsulation efficace d'acides nucleiques dans des liposomes de taille moyenne
STERNBERG liposome-DNA complexes for gene therapy
JP4450656B2 (ja) リポソームからなる遺伝子導入用キャリア
Sharma et al. Liposomes: vesicular system an overview
Kevadiya et al. Delivery of gene editing therapeutics
JP2007166946A (ja) 標的遺伝子の発現を抑制するための組成物
Arpac Overcoming biological barriers by lipid-based nanocarriers
Woodle et al. Liposomal antisense oligonucleotide therapeutics
Narainpersad Mitochondrial localisation and cellular uptake in vitro using novel ‘mitochondriotropic’liposomes.
Mkhwanazi The use of cholesterol-galacto compounds in liver directed gene delivery.
Palmer Development of stabilized plasmid lipid particles as intracellular gene delivery vehicles
MXPA01006862A (en) Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead